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Atherosclerotic cardiovascular disease is the major cause of 
death in patients with type 2 diabetes and is accelerated by the 
coexistence of hypertension. Arterial stiffness, which can be 
determined noninvasively through the measurement of pulse 
wave velocity (PWV), is associated with atherosclerosis and 
known to be an important risk factor of cardiovascular disease 
[1]. Currently, angiotensin II receptor blockers (ARBs) are 
recommended as the first-line drugs for treatment of hyper-
tension in type 2 diabetic patients. Several studies have report-
ed that ARBs also reduce arterial stiffness in patients with hy-
pertension and type 2 diabetes, independent of blood pressure 
reduction [2-4].
  In a recent issue of Diabetes & Metabolism Journal, Kim and 
colleagues [5] presented an article regarding the effect of an 
ARB on arterial stiffness in hypertensive patients with type 2 
diabetes. The authors reported that short-term (12 weeks) 
treatment with valsartan improved arterial stiffness in patients 
with type 2 diabetes and hypertension, and this effect was in-
fluenced by baseline glycemic status. Their study is one of very 
few studies in Asian people confirming the beneficial effects of 
ARB on arterial stiffness in hypertensive type 2 diabetic patients. 
However, there were some limitations to be considered before 
drawing a firm conclusion.
  First of all, as the authors mentioned, we cannot determine 
whether this effect is specific to ARB as there was no control 
group using anti-hypertensive agents of another class. Second, 
one of the drawbacks of this study was that PWV, the main 
outcome of the study, was measured in less than half (47/98) 
of the study participants. Although the authors showed that 
the baseline characteristics of the subgroup of patients with 
PWV estimation were similar to those of the whole group, we 
could not exclude the possibility of selection bias, and statisti-
cal power was diminished due to the small number of subjects. 
In addition, it is unclear why patients using insulin or antidia-
betic drugs such as metformin or thiazolidinediones were ex-
cluded. Third, the authors did not consider several important 
confounding factors which can potentially influence athero-
sclerotic process, such as concomitant use of lipid-lowering 
drugs, antiplatelet agents, or smoking. It has been reported 
that there was some difference in response of PWV to ARB 
between smokers and non-smokers [6]. Finally, there might 
be some differences other than baseline glycemic control be-
tween the “PWV decrease” and “no PWV decrease” group, 
such as a difference in baseline PWV values between the two 
groups. If glycemic control is an important factor affecting 
PWV, there must have been significant association between 
baseline PWV and HbA1c or fasting glucose levels. In addi-
tion, although it was not statistically significant, there was also 
some difference in the change in mean arterial pressure before 
and after treatment between the two groups (16.2 vs. 10.5 mm 
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Hg). Therefore, we cannot exclude the possibility that the “no 
PWV decrease” group may have higher blood pressure or poor 
medication compliance. 
  Although it has been established that ARB can improve ar-
terial stiffness in hypertensive patients with or without type 2 
diabetes, the mechanism has not been fully elucidated. The re-
ports of Kim et al. [5] confirmed the beneficial effects of ARBs 
on arterial stiffness but could not provide insight into the 
mechanism of improvement. The authors discussed several 
mechanisms suggested by other researchers such as reduction 
of vascular smooth muscle cell proliferation and fibrosis, en-
dothelial dysfunction, oxidative stress, or low-grade inflam-
mation. It would have been better if the study investigators 
were able to measure serum markers of inflammation or ex-
tracellular matrix metabolism, which have been shown to be 
affected by treatment with an ARB [3,7]. The authors of the 
study concluded that glycemic status at baseline is indepen-
dently associated with PWV improvement attributable to the 
action of valsartan. The identification of a significant correla-
tion between PWV and fasting glucose or HbA1c levels at 
baseline would be supporting evidence for this conclusion.
  This study by Kim and colleagues is a clinically important 
work showing the beneficial effect of ARB in addition to blood 
pressure reduction in Korean type 2 diabetic patients with hy-
pertension, although this study was only able to provide a lim-
ited conclusion and could not elucidate the mechanism of the 
observed effects. More large-scale, long-term clinical trials di-
rectly comparing clinical outcomes, such as cardiovascular 
morbidity or mortality, with those of other anti-hypertensive 
agents are warranted. In addition, more mechanistic studies 
are needed to provide a comprehensive understanding on the 
pathophysiology of atherosclerosis in type 2 diabetic and hy-
pertensive patients. Finally, I greatly appreciate the devotion of 
the study investigators to conduct such an important clinical 
study and wish them continued success in their future research. 
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